Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;53(3):483-92.
doi: 10.1007/s00592-015-0823-z. Epub 2016 Mar 14.

Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus

Ruben Tavares  1 , Marc Duclos  2 , Marie-Josée Brabant  2 , Daniella Checchin  3 , Nevzeta Bosnic  4 , Katherine Turvey  5 , Jorge Alfonso Ross Terres  6
Affiliations

Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus

Ruben Tavares et al. Acta Diabetol. 2016 Jun.

Abstract

Aims: To determine whether blood glucose test strip (BGTS) utilization in patients with type 2 diabetes (T2D) is associated with the type of diabetes therapy, classified according to hypoglycemic risk.

Methods: A retrospective, longitudinal (2006-2012) study of Canadian private drug plans (PDP) and Ontario Public Drug Programs (OPDP) prescription claims was conducted. Analyses were restricted to patients with T2D with or without a claim for BGTS. Daily BGTS utilization (TS/patient/day) was evaluated by diabetes therapy classified by hypoglycemic risk. Multivariate analyses were conducted to identify determinants of BGTS utilization.

Results: The T2D cohort comprised 5,759,591 observations from 1,949,129 claimants. Mean BGTS utilization was 0.84 TS/patient/day and differed between PDP and OPDP (0.66 vs. 1.00). Daily utilization was greatest in patients receiving therapy associated with a pre-defined high risk of hypoglycemia [insulin: basal + bolus (2.16), premixed (1.65), basal (1.16), other insulin regimens (2.13), and sulfonylureas (0.74)] versus non-sulfonylurea non-insulin-based regimens (0.52). For non-insulin therapy, BGTS utilization was greater for patients on multiple non-insulin therapies versus monotherapy (0.74 vs. 0.53 TS/patient/day). In multivariate analyses, drivers for BGTS utilization included insulin use, previous BGTS use, and female gender. Previous diabetes therapy and duration of therapy were negatively correlated with BGTS utilization.

Conclusions: BGTS utilization varies depending on the type of therapy used to treat T2D according to hypoglycemic risk. Decision making regarding BGTS needs to account for robust analyses of current utilization and its value in those settings, including in patients not receiving diabetes therapy and the prevalence of circumstances conducive to more intensive monitoring.

Keywords: Blood glucose self-monitoring; Type 2 diabetes mellitus; Utilization.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
An illustration of the longitudinal approach to accounting for diabetes therapy and allocation of BGTS utilization BGTS blood glucose test strips, TS test strips
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Berard LD, et al. Monitoring glycemic control. Can J Diabetes. 2013;37(Suppl 1):S35–S39. doi: 10.1016/j.jcjd.2013.01.017. - DOI - PubMed
    1. American Diabetes Association Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–S80. doi: 10.2337/dc14-S014. - DOI - PubMed
    1. International Diabetes Federation (2009) Self-monitoring of blood glucose in non-insulin treated type 2 diabetes. http://www.idf.org/webdata/docs/SMBG_EN2.pdf. Accessed Mar 2015
    1. Ryden L, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) Eur Heart J. 2013;34(39):3035–3087. doi: 10.1093/eurheartj/eht108. - DOI - PubMed
    1. National Institute for Health and Care Excellence (NICE) (2015) Type 2 diabetes: the management of type 2 diabetes. http://www.nice.org.uk/guidance/cg87/resources/guidance-type-2-diabetes-pdf. Accessed Mar 2015

LinkOut - more resources